Harnessing Metformin's Immunomodulatory Effects on Immune Cells to Combat Breast Cancer

• Published in: International journal of molecular sciences 2024-06, Vol.25 (11), p.5869
• Main Authors: Petrovic, Andjela, Jovanovic, Ivan, Stojanovic, Bojan, Dimitrijevic Stojanovic, Milica, Stojanovic, Bojana S, Jurisevic, Milena, Simovic Markovic, Bojana, Jovanovic, Marina, Jovanovic, Milan, Jovanovic, Mihailo, Gajovic, Nevena
• Format: Article
• Language: English
• Subjects: Animals; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - immunology; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cancer; Cancer therapies; Care and treatment; Cell Line, Tumor; Cytokines; Cytotoxicity; Dendritic cells; Development and progression; Diabetes; Diagnosis; Female; Genotype & phenotype; Immune system; Immunomodulating Agents - pharmacology; Immunotherapy; Investigations; Lymphocytes; MDSCs; Metformin; Metformin - pharmacology; Metformin - therapeutic use; Mice; Mice, Inbred BALB C; Myeloid-Derived Suppressor Cells - drug effects; Myeloid-Derived Suppressor Cells - immunology; Myeloid-Derived Suppressor Cells - metabolism; Natural Killer T-Cells - drug effects; Natural Killer T-Cells - immunology; Natural Killer T-Cells - metabolism; NKT cells; STAT4; T cells; T-Lymphocytes, Regulatory - drug effects; T-Lymphocytes, Regulatory - immunology; T-Lymphocytes, Regulatory - metabolism; Tregs; Tumors
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25115869

Metformin, a medication known for its anti-glycemic properties, also demonstrates potent immune system activation. In our study, using a 4T1 breast cancer model in BALB/C WT mice, we examined metformin's impact on the functional phenotype of multiple immune cells, with a specific emphasis on natural killer T (NKT) cells due to their understudied role in this context. Metformin administration delayed the appearance and growth of carcinoma. Furthermore, metformin increased the percentage of IFN-γ NKT cells, and enhanced CD107a expression, as measured by MFI, while decreasing PD-1 , FoxP3 , and IL-10 NKT cells in spleens of metformin-treated mice. In primary tumors, metformin increased the percentage of NKp46 NKT cells and increased FasL expression, while lowering the percentages of FoxP3 , PD-1 , and IL-10-producing NKT cells and KLRG1 expression. Activation markers increased, and immunosuppressive markers declined in T cells from both the spleen and tumors. Furthermore, metformin decreased IL-10 and FoxP3 Tregs, along with Gr-1 myeloid-derived suppressor cells (MDSCs) in spleens, and in tumor tissue, it decreased IL-10 and FoxP3 Tregs, Gr-1 , NF-κB , and iNOS MDSCs, and iNOS dendritic cells (DCs), while increasing the DCs quantity. Additionally, increased expression levels of MIP1a, STAT4, and NFAT in splenocytes were found. These comprehensive findings illustrate metformin's broad immunomodulatory impact across a variety of immune cells, including stimulating NKT cells and T cells, while inhibiting Tregs and MDSCs. This dynamic modulation may potentiate its use in cancer immunotherapy, highlighting its potential to modulate the tumor microenvironment across a spectrum of immune cell types.